NCT06096415View on ClinicalTrials.gov

Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

May 31, 2024

Conditions
Traumatic Brain InjuryCerebral Edema
Interventions
DRUG

ABX-101 1mg

ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)

DRUG

ABX-101 2mg

ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)

All Listed Sponsors
lead

Abalonex, LLC

INDUSTRY